• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Paul E. Goss, FRCP, MB BCh, PhD


  • Goss PE, Smith IE, O'Shaughnessy J, Ejlertsen B, Kaufmann M, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Chavarri-Guerra Y, Aktan G, Rappold E, Williams LS, Finkelstein DM, .Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.Lancet Oncol. 2013 Jan;14(1):88-96.
  • Higgins MJ, Liedke PE, Goss PE.Extended adjuvant endocrine therapy in hormone dependent breast cancer: The paradigm of the NCIC-CTG MA.17/BIG 1-97 trial.Crit Rev Oncol Hematol. 2012 Oct 29.
  • Wasan KM, Goss PE, Pritchard PH, Shepherd L, Tu D, Ingle JN.Lipid concentrations in postmenopausal women on letrozole after 5¬†years of tamoxifen: an NCIC CTG MA.17 sub-study.Breast Cancer Res Treat. 2012 Oct 23.
  • Vachon CM, Sasano H, Ghosh K, Brandt KR, Watson DA, Reynolds C, Lingle WL, Goss PE, Li R, Aiyar SE, Scott CG, Pankratz VS, Santen RJ, Ingle JN.Aromatase immunoreactivity is increased in mammographically dense regions of the breast.Breast Cancer Res Treat. 2011 Jan;125(1):243-52.
  • Goss PE, Chambers AF.Does tumour dormancy offer a therapeutic target?.Nat Rev Cancer. 2010 Dec;10(12):871-7. Review.
  • Ingle JN, Schaid DJ, Goss PE, Liu M, Mushiroda T, Chapman JA, Kubo M, Jenkins GD, Batzler A, Shepherd L, Pater J, Wang L, Ellis MJ, Stearns V, Rohrer DC, Goetz MP, Pritchard KI, Flockhart DA, Nakamura Y, Weinshilboum RM.Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors.J Clin Oncol. 2010 Nov 1;28(31):4674-82.
  • Joffe H, Partridge A, Giobbie-Hurder A, Li X, Habin K, Goss P, Winer E, Garber J.Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: a randomized, double-blind, placebo-controlled trial.Menopause.;17(5):908-16.
  • Cigler T, Tu D, Yaffe MJ, Findlay B, Verma S, Johnston D, Richardson H, Hu H, Qi S, Goss PE.A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women.Breast Cancer Res Treat. 2010 Apr;120(2):427-35.
  • Goss PE,Qi S,Hu H.Comparing the effects of atamestane, toremifene and tamoxifen alone and in combination, on bone, serum lipids and uterus in ovariectomized rats.J Steroid Biochem Mol Biol. 2009 Feb;113(3-5):233-40.
  • Chambers AF,Goss PE.Putative growth characteristics of micrometastatic breast cancer.Breast Cancer Res. 2008;10(6):114.
  • Goss PE,Muss HB,Ingle JN,Whelan TJ,Wu M.Extended adjuvant endocrine therapy in breast cancer: current status and future directions.Clin Breast Cancer. 2008 Oct;8(5):411-7. Review.
  • Goss P, Allan AL, Rodenhiser DI, Foster PJ, Chambers AF.New clinical and experimental approaches for studying tumor dormancy: does tumor dormancy offer a therapeutic target?.APMIS.;116(7-8):552-68. Review.
  • Goss PE.Extending the benefits of adjuvant therapy in early HR+ breast cancer.Breast Cancer Res Treat. 2008 Dec;112 Suppl 1:45-52.
  • Miller WR,Bartlett J,Brodie AM,Brueggemeier RW,di Salle E,Lonning PE,Llombart A,Maass N,Maudelonde T,Sasano H,Goss PE.Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?.Oncologist. 2008 Aug;13(8):829-37. Review.
  • Pater JL, Goss P, Meyer R.Stopping trials for benefit can (sometimes) benefit patients.J Clin Oncol. 2008 Jun 1;26(16):2787-8; author reply 2788.
  • Ma XJ, Salunga R, Dahiya S, Wang W, Carney E, Durbecq V, Harris A, Goss P, Sotiriou C, Erlander M, Sgroi D.A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast Cancer.Clin Cancer Res. 2008 May 1;14(9):2601-8.
  • Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E.Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.Circulation. 2008 Apr 22;117(16):2104-13.
  • Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Tu D.Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.J Clin Oncol. 2008 Apr 20;26(12):1948-55.
  • Muss HB, Tu D, Ingle JN, Martino S, Robert NJ, Pater JL, Whelan TJ, Palmer MJ, Piccart MJ, Shepherd LE, Pritchard KI, He Z, Goss PE.Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.J Clin Oncol. 2008 Apr 20;26(12):1956-64.
  • Pater J, Tu D, Shepherd L, Ingle JN, Goss PE.Decision making in adjuvant trials in breast cancer: the NCIC CTG MA.17 trial as an example.Breast Cancer Res Treat. 2008 Mar;108(2):265-9.
  • Goss PE, Richardson H, Chlebowski R, Johnston D, Sarto GE, Maunsell E, Ingle JN, Ales-Martinez JE.National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: evaluation of exemestane to prevent breast cancer in postmenopausal women.Clin Breast Cancer. 2007 Dec;7(11):895-900.
  • Chapman JA, Meng D, Shepherd L, Parulekar W, Ingle JN, Muss HB, Palmer M, Yu C, Goss PE.Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer.Journal of the National Cancer Institute. 2008 Feb 20;100(4):252-60.
  • Ryan PD, Goss PE.The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer.Oncologist. 2008 Jan;13(1):16-24. Review.
  • Buzdar AU, Coombes RC, Goss PE, Winer EP.Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer.Cancer. 2008 Feb 1;112(3 Suppl):700-9.
  • Come SE, Buzdar AU, Ingle JN, Johnston SR, Brodie AM, Coombes RC, Miller WR, Pritchard KI, Winer EP, Zujewski JA, Goss PE.Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference.Cancer. 2008 Feb 1;112(3 Suppl):673-8.
  • Gligorov J, Pritchard K, Goss P.Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis.Breast. 2007 Dec;16 Suppl 3:S1-9. Review.
  • Goss PE.Letrozole in the extended adjuvant setting: MA.17.Breast Cancer Res Treat. 2007;105 Suppl 1:45-53.
  • Goss P, Bondarenko IN, Manikhas GN, Pendergrass KB, Miller WH Jr, Langecker P, Blanchett D.Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer.J Clin Oncol. 2007 Nov 1;25(31):4961-6.
  • Wu M, Goss PE.Update on the use of letrozole in breast cancer.Expert Opin Pharmacother. 2007 Oct;8(14):2329-45. Review.
  • Goss P, Wu M.Application of aromatase inhibitors in endocrine responsive breast cancers.Breast. 2007 Dec;16 Suppl 2:S114-9. Review.
  • Moy B, Goss PE.Lapatinib-associated toxicity and practical management recommendations.Oncologist. 2007 Jul;12(7):756-65. Review.
  • Goss P, von Eichel L.Summary of aromatase inhibitor trials: the past and future.J Steroid Biochem Mol Biol. 2007 Aug-Sep;106(1-5):40-8.
  • Santen RJ, Demers L, Ohorodnik S, Settlage J, Langecker P, Blanchett D, Goss PE, Wang S.Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy.Steroids. 2007 Jul;72(8):666-71.
  • Goss PE, Qi S, Hu H, Cheung AM.The effects of atamestane and toremifene alone and in combination compared with letrozole on bone, serum lipids and the uterus in an ovariectomized rat model.Breast Cancer Res Treat. 2007 Jul;103(3):293-302.
  • Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL,.Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.J Clin Oncol. 2007 May 20;25(15):2006-11.
  • Moy B, Goss PE.TEACH: Tykerb evaluation after chemotherapy.Clin Breast Cancer. 2007 Feb;7(6):489-92.
  • del Carmen MG, Halpern EF, Kopans DB, Moy B, Moore RH, Goss PE, Hughes KS.Mammographic breast density and race.AJR Am J Roentgenol. 2007 Apr;188(4):1147-50.
  • Booth CM, Pater JL, Goss PE.Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant tamoxifen.Cancer. 2007 May 1;109(9):1927-8; author reply 1928.
  • Goss PE, Strasser-Weippl K, Qi S, Hu H.Effects of liarozole fumarate (R85246) in combination with tamoxifen on N-methyl-N-nitrosourea (MNU)-induced mammary carcinoma and uterus in the rat model.BMC Cancer. 2007;7:26.
  • Delea TE, Karnon J, Goss PE.Conclusions regarding relative cost-utility of alternative strategies for use of aromatase inhibitors in postmenopausal women with early breast cancer are premature.Ann Oncol. 2007 Jan;18(1):197-8; author reply 198-9.
  • Vachon CM, Ingle JN, Suman VJ, Scott CG, Gottardt H, Olson JE, Goss PE.Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen.Breast. 2007 Apr;16(2):204-10.
  • Chien AJ, Goss PE.Aromatase inhibitors and bone health in women with breast cancer.J Clin Oncol. 2006 Nov 20;24(33):5305-12. Review.
  • Moy B, Goss PE.Lapatinib: current status and future directions in breast cancer.Oncologist. 2006 Nov-Dec;11(10):1047-57. Review.
  • Ingle JN, Tu D, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE.Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial.Breast Cancer Res Treat. 2006 Oct;99(3):295-300.
  • Moy B, Tu D, Pater JL, Ingle JN, Shepherd LE, Whelan TJ, Goss PE.Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer.Ann Oncol. 2006 Nov;17(11):1637-43.
  • Moy B, Goss PE.Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches.Clin Cancer Res. 2006 Aug 15;12(16):4790-3. Review.
  • Ryan PD, Goss PE.Adjuvant hormonal therapy in peri- and postmenopausal breast cancer.Oncologist. 2006 Jul;11(7):718-31. Review.
  • Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE.Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.J Clin Oncol. 2006 Aug 1;24(22):3629-35.
  • Goss PE.Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.Semin Oncol. 2006 Apr;33(2 Suppl 7):S8-12.
  • Cigler T, Goss PE.Aromatase inhibitor withdrawal response in metastatic breast cancer.J Clin Oncol. 2006 Apr 20;24(12):1955-6.
  • Karnon J, Delea T, Johnston SR, Smith R, Brandman J, Sung J, Goss PE.Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective.Pharmacoeconomics. 2006;24(3):237-50.
  • Pritchard KI, Goss PE, Shepherd L.The extended adjuvant NCIC CTG MA.17 trials: initial and rerandomization studies.Breast. 2006 Feb;15 Suppl 1:S14-20. Review.
  • Ryan PD, Goss PE.The evolving role of aromatase inhibitors in the treatment of early-stage breast cancer.Nat Clin Pract Oncol. 2005 Dec;2(12):596-7.
  • Suen TC, Tang MS, Goss PE.Model of transcriptional regulation of the BRCA1-NBR2 bi-directional transcriptional unit.Biochim Biophys Acta. 2005 May 1;1728(3):126-34.
  • Strasser-Weippl K, Goss PE.Advances in adjuvant hormonal therapy for postmenopausal women.J Clin Oncol. 2005 Mar 10;23(8):1751-9.
  • Goss PE, Qi S, Cheung AM, Hu H, Mendes M, Pritzker KP.The selective estrogen receptor modulator SCH 57068 prevents bone loss, reduces serum cholesterol and blocks estrogen-induced uterine hypertrophy in ovariectomized rats.J Steroid Biochem Mol Biol. 2004 Sep;92(1-2):79-87.
  • Goss PE, Qi S, Josse RG, Pritzker KP, Mendes M, Hu H, Waldman SD, Grynpas MD.The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats.Bone. 2004 Mar;34(3):384-92.
  • Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL.A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.N Engl J Med. 2003 Nov 6;349(19):1793-802.